A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population Approach
暂无分享,去创建一个
H. Colom | D. Hesselink | N. Lloberas | J. Torras | J. Grinyó | O. Bestard | L. Elens | T. Gelder | R. H. Schaik | Josep M. Cruzado | F. Andreu
[1] Tacrolimus , 2019, Reactions Weekly.
[2] H. Colom,et al. The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation , 2017, Pharmacogenetics and genomics.
[3] A. Jardine,et al. High Intrapatient Tacrolimus Variability Is Associated With Worse Outcomes in Renal Transplantation Using a Low-Dose Tacrolimus Immunosuppressive Regime , 2017, Transplantation.
[4] W. Weimar,et al. A high intrapatient variability in tacrolimus exposure is associated with poor long‐term outcome of kidney transplantation , 2016, Transplant international : official journal of the European Society for Organ Transplantation.
[5] D. Lambrechts,et al. Effect of ABCB1 diplotype on tacrolimus disposition in renal recipients depends on CYP3A5 and CYP3A4 genotype , 2016, The Pharmacogenomics Journal.
[6] A. Åsberg,et al. Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipients—A Prospective, Randomized Study , 2015, Transplantation.
[7] I. Trocóniz,et al. Population pharmacokinetic analysis of tacrolimus in Mexican paediatric renal transplant patients: role of CYP3A5 genotype and formulation. , 2015, British journal of clinical pharmacology.
[8] D. Hesselink,et al. Dosing algorithms for initiation of immunosuppressive drugs in solid organ transplant recipients , 2015, Expert opinion on drug metabolism & toxicology.
[9] H. Colom,et al. Development of a Population PK Model of Tacrolimus for Adaptive Dosage Control in Stable Kidney Transplant Patients , 2015, Therapeutic drug monitoring.
[10] A. Israni,et al. OPTN/SRTR 2013 Annual Data Report: Kidney , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[11] D. Kuypers,et al. Combined effects of CYP3A5*1, POR*28, and CYP3A4*22 single nucleotide polymorphisms on early concentration-controlled tacrolimus exposure in de-novo renal recipients , 2014, Pharmacogenetics and genomics.
[12] D. Hesselink,et al. Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks. , 2014, British journal of clinical pharmacology.
[13] J. D. de Fijter,et al. Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation , 2014, CPT: pharmacometrics & systems pharmacology.
[14] D. Hesselink,et al. The Role of Pharmacogenetics in the Disposition of and Response to Tacrolimus in Solid Organ Transplantation , 2014, Clinical Pharmacokinetics.
[15] C. Polidori,et al. Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients. , 2013, World journal of gastroenterology.
[16] R. Jelliffe,et al. Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation , 2013, Transplant international : official journal of the European Society for Organ Transplantation.
[17] V. Haufroid,et al. Impact of CYP3A4*22 Allele on Tacrolimus Pharmacokinetics in Early Period After Renal Transplantation: Toward Updated Genotype-Based Dosage Guidelines , 2013, Therapeutic drug monitoring.
[18] A. Åsberg,et al. Importance of hematocrit for a tacrolimus target concentration strategy , 2013, European Journal of Clinical Pharmacology.
[19] J. Barrett,et al. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis , 2013, Pharmacogenetics and genomics.
[20] A. Israni,et al. OPTN/SRTR 2011 Annual Data Report: Kidney , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[21] A. Israni,et al. Lower Calcineurin Inhibitor Doses in Older Compared to Younger Kidney Transplant Recipients Yield Similar Troughs , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[22] A. V. van Zuilen,et al. Drug-drug interactions between antiretroviral and immunosuppressive agents in HIV-infected patients after solid organ transplantation: a review. , 2012, AIDS patient care and STDs.
[23] V. Haufroid,et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. , 2011, Clinical chemistry.
[24] V. Haufroid,et al. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients. , 2011, Pharmacogenomics.
[25] P. Marquet,et al. Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations--twice daily Prograf and once daily Advagraf. , 2011, British journal of clinical pharmacology.
[26] Andrew C. Hooker,et al. Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models , 2011, The AAPS Journal.
[27] M. Loriot,et al. Optimization of Initial Tacrolimus Dose Using Pharmacogenetic Testing , 2010, Clinical pharmacology and therapeutics.
[28] V. Haufroid,et al. CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation. , 2010, Pharmacogenomics.
[29] V. Haufroid,et al. Time of Drug Administration, CYP3A5 and ABCB1 Genotypes, and Analytical Method Influence Tacrolimus Pharmacokinetics: A Population Pharmacokinetic Study , 2009, Therapeutic drug monitoring.
[30] R. Savic,et al. Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and Solutions , 2009, The AAPS Journal.
[31] F. Oppenheimer,et al. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[32] V. Haufroid,et al. Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference , 2009, Therapeutic drug monitoring.
[33] P. Wallemacq,et al. A Fast Ultra-Performance Liquid Chromatography Method for Simultaneous Quantification of Mycophenolic Acid and Its Phenol- and Acyl-Glucuronides in Human Plasma , 2009, Therapeutic drug monitoring.
[34] V. Haufroid,et al. 1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation , 2007, Pharmacogenetics and genomics.
[35] Mats O. Karlsson,et al. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies , 2007, Journal of Pharmacokinetics and Pharmacodynamics.
[36] U. Kunzendorf,et al. CYP3A5 Genotype Markedly Influences the Pharmacokinetics of Tacrolimus and Sirolimus in Kidney Transplant Recipients , 2007, Clinical pharmacology and therapeutics.
[37] E. Niclas Jonsson,et al. Erratum to "PsN-Toolkit - A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM" [Comput. Methods Prog. Biomedicine 79 (2005) 241-257] , 2005, Comput. Methods Programs Biomed..
[38] Zhi-Hong Liu,et al. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation , 2005, Clinical transplantation.
[39] E. Niclas Jonsson,et al. PsN-Toolkit - A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM , 2005, Comput. Methods Programs Biomed..
[40] D. Holt,et al. Tacrolimus Pharmacogenetics: The CYP3A5*1 Allele Predicts Low Dose-Normalized Tacrolimus Blood Concentrations in Whites and South Asians , 2005, Transplantation.
[41] A. McLachlan,et al. Factors affecting variability in distribution of tacrolimus in liver transplant recipients. , 2003, British journal of clinical pharmacology.
[42] P. Beaune,et al. Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients12 , 2003, Transplantation.
[43] W. Weimar,et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR‐1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus , 2003, Clinical pharmacology and therapeutics.
[44] C. Staatz,et al. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients , 2002, Clinical pharmacology and therapeutics.
[45] L. Sheiner,et al. Evaluating Pharmacokinetic/Pharmacodynamic Models Using the Posterior Predictive Check , 2001, Journal of Pharmacokinetics and Pharmacodynamics.
[46] I. Bekersky,et al. Effect of Low‐ and High‐Fat Meals on Tacrolimus Absorption following 5 mg Single Oral Doses to Healthy Human Subjects , 2001, Journal of clinical pharmacology.
[47] U. Christians,et al. The pharmacokinetics and metabolic disposition of tacrolimus: A comparison across ethnic groups , 2001, Clinical pharmacology and therapeutics.
[48] Mats O. Karlsson,et al. Automated Covariate Model Building Within NONMEM , 1998, Pharmaceutical Research.
[49] N. Undre,et al. Pharmacokinetics of tacrolimus (FK506) in paediatric liver transplant recipients , 1998, European Journal of Drug Metabolism and Pharmacokinetics.
[50] T. Starzl,et al. Clinical Pharmacokinetics of Tacrolimus , 1995, Clinical pharmacokinetics.
[51] M. O. Karlsson,et al. The importance of modeling interoccasion variability in population pharmacokinetic analyses , 1993, Journal of Pharmacokinetics and Biopharmaceutics.
[52] S. Todo,et al. Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. , 1990, Transplantation proceedings.
[53] Lewis B. Sheiner,et al. Some suggestions for measuring predictive performance , 1981, Journal of Pharmacokinetics and Biopharmaceutics.
[54] Kiyoshi Yamaoka,et al. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations , 1978, Journal of Pharmacokinetics and Biopharmaceutics.
[55] V. Haufroid,et al. CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy. , 2013, Pharmacogenomics.
[56] A. Prémaud,et al. Tacrolimus Population Pharmacokinetic-Pharmacogenetic Analysis and Bayesian Estimation in Renal Transplant Recipients , 2009, Clinical pharmacokinetics.
[57] C. Staatz,et al. Clinical Pharmacokinetics and Pharmacodynamics of Mycophenolate in Solid Organ Transplant Recipients , 2007, Clinical pharmacokinetics.
[58] C. Staatz,et al. Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation , 2004, Clinical pharmacokinetics.